When: Constructive retatrutide EU data readout

Then: Complete full position build-out

HOLD

• Technical setup is broken: price below 10 EMA at 11.42 and 50 SMA at 11.80; MACD improvement from -10.88 to -5.93 is only one week of data and does not confirm trend reversal
• Valuation at 24x forward P/E is not attractive for a trillion-dollar market cap; PEG of 1.1 depends on accurate estimates and compresses if 47% revenue growth normalizes
• Berenberg price target of 1400 implies only 23% upside, not the 50-100% asymmetric opportunity the aggressive case suggests
• Beta of 0.5 does not protect against idiosyncratic risk; LLY already down ~12% from 52-week high of 1292
• FOMC meeting tomorrow has 94% odds of no cuts priced in; asymmetry lies in hawkish surprise that could push 10-year through 5% and re-rate growth multiples lower
• Retatrutide binary readout presents 5-8% downside risk on neutral data and 15% gap risk on disappointment, in a stock already below its 50 SMA
• GLP-1 physician payment controversy (270,000 doctors paid, some up to $1 million) creates regulatory and congressional hearing risk that has zero allocation in the aggressive framework
• Balance sheet now meaningfully levered with net debt of $46 billion and debt-to-equity of 1.62 post Q2 acquisition
• Aggressive trade plan of adding on weakness to 1115 with stop at 1065 represents 4-5% position-level risk that is not justified given the risk profile

→ vs aggressive: Technical coiled spring thesis relies on one week of MACD improvement (from -10.88 to -5.93), ignoring that price remains below the 10 EMA at 11.42, below the 50 SMA at 11.80, and in the lower third of the Bollinger band; the August rally also improved before rolling over

→ vs aggressive: Valuation celebration of 24x forward P/E ignores that this is not cheap for a trillion-dollar company; the 23% upside to the 1400 price target does not represent the 50-100% asymmetric opportunity claimed, and that catalyst is already in the stock

→ vs aggressive: Beta of 0.5 does not immunize against idiosyncratic risk; LLY has more idiosyncratic risk on the calendar in the next two weeks than any prior two-week period this year

→ vs aggressive: FOMC dismissal is reckless; with 94% odds of no cuts, asymmetry lies in surprise, and a hawkish dot plot compounds with the retatrutide readout as correlated shocks

→ vs aggressive: Retatrutide base rate argument is selective; the aggressive framing assumes past pipeline success but ignores that even a neutral readout (not a failure) could send the stock down 5-8% on positioning, and disappointment is 15% gap risk

→ vs aggressive: GLP-1 physician payment story (270,000 doctors paid, some up to $1 million) is zeroed out in the aggressive framework but represents regulatory and congressional risk that can move pharma stocks 20% in a week

→ vs aggressive: Balance sheet leverage (net debt of $46 billion, D/E of 1.62) is being ignored, and the aggressive add-on proposal at 1115 with stop at 1065 creates 4-5% position-level risk that does not match the advertised 6-to-1 reward-to-risk

HOLD at neutral weight baseline with tiered scaling-in framework; modest overweight of 100-110% of benchmark weight after confirmation triggers met; pair with macro hedges (long energy, long defense, or short duration) for hawkish regime protection

• MACD histogram improved 45% in one week but stock remains below 10 EMA, below 50 SMA, in lower third of Bollinger band
• LLY trades 12% below 52-week high with beta of 0.5
• Berenberg upgrade moved stock only 1.6% intraday; PT-driven moves in mega-cap pharma typically unfold over 6-12 weeks
• Berenberg price target implies 23% upside to $1400
• FOMC presents asymmetric risk: 94% no-cut odds means positioned for hawkish outcomes, any hawkish dot plot could compress multiples
• Aggressive analyst risks adding to position before FOMC resolution; potential 5-8% gap on merely neutral retatrutide readout (non-beat)
• Conservative 'wait for full confirmation' approach forfeits first 10-15% of move before entry at 50 SMA/1180 with RSI above 50
• Doctor-payment story involving 270,000 physicians is stale news already circulating; not a pending binary catalyst with 20% downside as conservative frames it
• Low-beta stock provides structural lower correlation to duration trade but does not immunize against idiosyncratic drawdowns
• Tiered trigger 1: Close above 10 EMA at 1142 with rising RSI and no hawkish FOMC shock → add 25% of intended position size
• Tiered trigger 2: Reclaims 50 SMA at 1180 with RSI above 50 → add another 25%
• Tiered trigger 3: Full conviction add only on constructive retatrutide data print
• Trim trigger: Below 1115 on volume → trim to underweight
• Exit trigger: Below 1076 → exit position
• Time horizon: 2-4 week holding period to collect FOMC, retatrutide readout, and Foundayo commercial uptake data

→ vs aggressive: MACD histogram 45% weekly improvement is 'pattern-matching dressed up in quantitative language' with stock still below key moving averages; FOMC positioning into 94% no-cut odds is 'kamikaze' not 'productive' aggression; low beta provides no immunization against idiosyncratic drawdowns or duration compression

→ vs conservative: 'Wait for full confirmation' at 50 SMA/1180 forfeits first 10-15% of the move to retail-priced institutional entry; Berenberg PT not fully priced at 1.6% intraday given 6-12 week typical PT-driven move realization; doctor-payment story is stale news not a pending 20% downside binary catalyst; over-indexed on tail risk that conflates story existence with story stock-moving potential tomorrow